64th ASH Annual Meeting and Exposition: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, genomics, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Biological Processes, Human

353-355 (Ernest N. Morial Convention Center)

Moderators:

Alice S. Mims, MD, The Ohio State University Comprehensive Cancer Center and Gautam Borthakur, MD, University of Texas MD Anderson Cancer Center, Department of Leukemia

Disclosures:

Mims: Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Other: Data Safety and Monitoring Board; BMS: Membership on an entity's Board of Directors or advisory committees; Ryvu: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Data Safety and Monitoring Board; Zentalis: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees.

Studies in this section describe the impact of specific genomic aberrations on prognosis in patients with acute myeloid leukemia.

4:30 PM

595

Mutation Spectrum of FLT3 and Significance of Non–Canonical FLT3 Mutations in Hematological Malignancies

Shuai-Shuai Ge^1,2^*, Xiangdong Shen^1,2^*, Tianmei Wu³^*, Jiahui Du⁴^*, Haiping Dai^1,2^*, Qiaocheng Qiu^1,2^*, Songbai Liu, PhD⁴^*, Depei Wu^1,2 and Shengli Xue^1,2^*

¹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
³Gusu District Maternal and Child Health Center, Suzhou, China
⁴Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China

4:45 PM

596

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, MD, MBBS, DM¹^*, Nicholas Short, MD², Abhishek Maiti, MBBS¹, Hussein A Abbas, MD, PhD¹, Naval Daver, MD¹, Naveen Pemmaraju, MD¹, Sherry A. Pierce, BSN, BA¹^*, Kelly S. Chien, MD¹, Koji Sasaki, MD¹, Danielle Hammond, MD¹, Gautam Borthakur, MD¹, Farhad Ravandi, MD¹, Hagop Kantarjian, MD³ and Courtney D. DiNardo, MD, MSCE¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 PM

597

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Michael J. Hochman, MD¹, Megan Othus, PhD², Robert P. Hasserjian, MD³, Alexander J. Ambinder, MD, MPH¹, Andrew M. Brunner, MD⁴, Mary-Elizabeth M. Percival, MD^5,6, Christopher S. Hourigan, MD⁷, Ronan Swords, MD PhD⁸, Amy E. DeZern, MD¹, Elihu H. Estey, M.D.^5,6 and Judith E. Karp, MD¹

¹Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
²Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
³Department of Pathology, Massachusetts General Hospital, Boston, MA
⁴Mass General Cancer Center, Massachusetts General Hospital, Boston, MA
⁵Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
⁶Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
⁷Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁸Knight Cancer Institute, Oregon Health & Science University, Portland

5:15 PM

598

Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia

Abdul Moiz Khan, MD¹, Sushmitha Nanja Reddy, MBBS²^*, Mai M M Aly, MD^3,4^*, Vikram Dhillon, DO²^*, Ali Al Sbihi, MD²^*, Tariq Kewan, MD⁴^*, Waled Bahaj, MD⁴, Carmelo Gurnari, MD^4,5, Bayan Al-Share, MD⁶^*, Gregory Dyson¹^*, Valeria Visconte, PhD⁴ and Suresh Kumar Balasubramanian, MD^4,7

¹Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI
²Department of Internal Medicine, Wayne State University, Detroit, MI
³Assiut University Hospital, Clinical Hematology Unit, Internal Medicine Department,, Assiut, Egypt
⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁵Department of Biomedicine and Prevention, Ph.D. in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
⁶Monument Health Cancer Care Institute, Rapid City, SD
⁷Department of Oncology, Wayne State University/ Karmanos Cancer Institute, Detroit, MI

5:30 PM

599

Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, MD¹, Ehab L. Atallah, MD², Rory M. Shallis, MD³, Antoine N. Saliba, MD⁴, Maximilian F. Stahl, MD⁵, Jan Philipp Bewersdorf, MD⁶, Justin Grenet, MD⁷, Anand Ashwin Patel, MD⁸, Yasmin Abaza, MD⁹, Guru Subramanian Guru Murthy, MBBS¹⁰, Adam S Duvall, MD¹¹, Madelyn Burkart, MD¹², Neil Palmisiano, MD, MS¹³, Michal Jakub Kubiak, MD¹⁴, Vamsi K. Kota, MD¹⁵, Shira Dinner, MD⁹, Aaron D Goldberg, MD, PhD¹⁶ and Mark R. Litzow, MD⁴

¹Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL
²Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
³Yale University School of Medicine, New Haven, CT
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Department of Medical Oncology, Dana-Farber Institute, Boston, MA
⁶Department of Internal Medicine, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT
⁷New York Presbyterian/Weill-Cornell Medical Center, New York, NY
⁸Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
⁹Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
¹⁰Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
¹¹Department of Medicine, University of Chicago, Chicago, IL
¹²Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
¹³Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
¹⁴Augusta University, Augusta, GA
¹⁵Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA
¹⁶Memorial Sloan Kettering Cancer Center, New York, NY

5:45 PM

600

Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019

Abdul Rahman Al Armashi, MD¹^*, Anas Al Zubaidi, MD²^*, Dina Elantably, MD³^*, Jiasheng Wang, MD¹ and Akram Alkrekshi, MD⁴^*

¹Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
²Johns Hopkins University, Baltimore, MD
³Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Cleveland, OH
⁴Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Westlake, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

613.O3.6 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia